Navigation Links
First Telescopic Implant in Connecticut for Macular Degeneration
Date:3/7/2013

CHESHIRE, Conn., March 7, 2013 /PRNewswire-iReach/ -- Dr. Randolph Kinkade has been recently interviewed on WFSB's Your Health and WTNH's Health News discussing this new technology.  Dr. Kinkade, a Connecticut optometrist, is a founding member of the International Academy of Low Vision Specialists. 

About the size of an eraser tip, the Implantable Miniature Telescope shows promise for some patients who are legal blind due to macular degeneration.  Macular degeneration is the leading cause of permanent vision loss in older Americans. 

"I have been fitting Spectacle Miniature Telescopes in glasses for improving eyesight for over twenty years to help patients improve their ability to read, write and watch television", says Dr. Kinkade. "For certain patients we now have the ability to replace a developing cataract in their eye with a micro-telescope that returns some very useful vision."

The newly FDA and Medicare approved telescope is placed in only one eye.  The telescope implant focuses and enlarged image onto healthier parts of the macula and retina at the back of the eye.  The other eye provides the necessary peripheral or side vision for walking and performing other tasks.

Dr. Kinkade's treatment role is with candidate selection and determining which eye gets the implant.  He also spends considerable time with patients after surgery guiding them to use their new vision.  Dr. Mark Milner will be doing the surgery.

"The implant is not a cure for macular degeneration, but a rehabilitation tool to return some very important vision", says Dr. Kinkade.  "Patients will need to relearn to see and use additional low vision aids to maximize their vision."

For pictures of the telescopic implant, educational videos and information about the treatment program please visit http://LowVisionEyeglasses.com

Dr. Kinkade office telephone is (800) 756-0766 and he can be emailed at rkinkade@optonline.net

About Macular Degeneration

  • Macular degeneration affects the macula, the part of the retina needed for detail central vision. Patients do see things to the side with their peripheral vision, but it is too blurry for detailed vision like reading.
  • The first signs of macular degeneration may include wavy lines, distortion, or blurry spots when reading.
  • There are two types of macular degeneration (wet and dry).  There is no medical treatment for the dry form of the disease.
  • Low vision rehabilitation provides Spectacle Miniature Telescopes and other magnification aids to help restore lost vision.

Media Contact: Randolph Kinkade , OD, MPH, Low Vision Consulting, (800) 756-0766, rkinkade@optonline.net

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Low Vision Consulting
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Thoratec Schedules First Quarter Conference Call, Webcast
3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):